Browse
Submit Data
Databases
API
Help

Dataset Information

148 Views

0 Connections

2 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phosphoproteomics Profiling of Non-Small Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator

ABSTRACT: Activation of protein phosphatase 2A (PP2A) is a promising anti-cancer therapeutic strategy given this tumor suppressor’s ability to coordinately downregulate multiple pathways involved with growth and proliferation.Here, we studied the global signaling response signature of a novel small molecule activator of PP2A (SMAP). Through an exploration of the global phosphoproteomicalterations of two KRAS mutated non-small cell lung cancer (NSCLC) cell lines (A549 and H358)in the context of PP2A activation, we sought to identify the pathway-level perturbations and uncover candidate proteins that are potentially key targets of SMAP regulation.

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Lung, Permanent Cell Line Cell

DISEASE(S): Bronchiolo-alveolar Adenocarcinoma

SUBMITTER: Danica Wiredja

LAB HEAD: Mark R. Chance

PROVIDER: PXD005698 | Pride | 2018-07-05

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.

Wiredja Danica D DD Ayati Marzieh M Mazhar Sahar S Sangodkar Jaya J Maxwell Sean S Schlatzer Daniela D Narla Goutham G Koyutürk Mehmet M Chance Mark R MR

Proteomics 20171025 22

Activation of protein phosphatase 2A (PP2A) is a promising anticancer therapeutic strategy, as this tumor suppressor has the ability to coordinately downregulate multiple pathways involved in the regulation of cellular growth and proliferation. In order to understand the systems-level perturbations mediated by PP2A activation, we carried out mass spectrometry-based phosphoproteomic analysis of two KRAS mutated non-small cell lung cancer (NSCLC) cell lines (A549 and H358) treated with a novel sma ...[more]

PMID: 28961369

Similar Datasets

Proteomic Explorations of Autism Brain - Part 1

Project description:Autism Spectrum Disorder (ASD) is a group of common neurodevelopmental conditions with impairments in socialization, communication and restricted behaviors. Only a minority of ASD cases are determined to have a definitive etiology and the pathogenesis of most ASD remains poorly understood. In this study, we made use of the power of proteomics, heretofore little utilized in the study of the biology of ASD, and analyzed the proteomes of two brain regions, Brodmann area 19 (BA19) and posterior inferior cerebellum (CB), from 9 idiopathic ASD cases/9 matched controls by label-free HPLC-tandem mass spectrometry (MS) and validated the differentially expressed protein findings with selected-reaction monitoring MS. The data revealed marked differences between ASD and control brain proteomes for both brain regions, with numerous differentially expressed proteins, although the proteomic difference between brain regions was not attenuated in ASD brain. Bioinformatic analyses based on the differentially expressed proteins highlighted multiple canonical pathways and protein-protein interaction networks that are implicated in the differential biology of ASD vs. controls. Canonical pathways involving glutamate receptor signaling and RXR activation were enriched for both BA19 and CB; others such as cell-cell junction signaling and fatty acid oxidation were enriched for BA19 and CB, respectively. Network analysis revealed a protein interaction network related to synaptic biology in BA19 and another involving cytoskeletal/vesicular functions in CB. Upstream regulator analysis for both regions revealed multiple neurodegeneration-associated proteins. The finding of several shared canonical pathways and upstream regulators for both regions underscores likely common ASD pathophysiology that has distinctive regional expression.

2019-09-16 | PXD012755 | Pride

Proteomic investigations of human HERC2 mutants: insights into the pathobiology of a neurodevelopmental disorder

Project description:HERC2 is a giant protein with E3 ubiquitin ligase activity and other known and suspected functions. Mutations of HERC2 are implicated in the pathogenesis of various cancers and result in various severe neurological conditions in Herc2-mutant mice. Recently, a pleotropic autosomal recessive HERC2-associated syndrome of intellectual disability, autism and variable neurological deficits was described; its pathogenetic basis is largely unknown. Using peripheral blood-derived lymphoblasts from 3 persons with homozygous HERC2 variants and 14 age- and gender-matched controls, we performed unbiased HPLC-tandem mass spectrometry-based proteomic analyses to provide insights into HERC2-mediated pathobiology. We found that out of 3427 detected proteins, there were 812 differentially expressed proteins between HERC2-cases vs. controls. 184 canonical pathways were enriched after FDR adjustment, including mitochondrial function, energy metabolism, EIF2 signaling, immune functions, ubiquitination and DNA repair. Ingenuity Pathway Analysis® identified 209 upstream regulators that could drive the differential expression, prominent amongst which were neurodegeneration-associated proteins. Differentially expressed protein interaction networks highlighted themes of immune function/dysfunction, regulation of cell cycle/cell death, and energy metabolism. Overall, the analysis of the HERC2-associated proteome revealed striking differential protein expression between cases and controls. The large number of differentially expressed proteins likely reflects HERC2’s multiple domains and numerous interacting proteins. Our canonical pathway and protein interaction network findings suggest derangements of multiple pathways in HERC2-associated disease.

2019-03-27 | PXD012644 | Pride

Proteomic Investigations into Adult Polyglucosan Body Disease

Project description:Adult polyglucosan body disease is a rare autosomal recessive neurologicla disorder with progressive paralysis, sensory deficits, and neurogenic bladder usually manifesting late in life. The disease is derived from glycogen branching enzyme deficiency that leads to aggregation of polyglucosan bodies in many cell types. This project focuses on delinating disease mechanisms in APBD through studying the proteomes of lymphoblasts of 3 patients with APBD and comparing them to several controls.

2023-11-08 | PXD012558 | Pride

Cross-linking of mouse laminin 111

Project description:Laminin, a ~800 kD heterotrimeric protein, is a major functional component of the extracellular matrix, contributing to tissue development and maintenance. We used cross-linking and mass spectrometry to determine the order of subunits in the ~750 Å trimeric coiled-coil oligomerization domain of laminin and to achieve an estimate of the register of the three subunits along the length of the coiled coil.

2016-12-22 | PXD004898 | Pride

Dynamic adaptation of myocardial proteome during heart failure development after induction of left ventricular pressure overload in mice

Project description:We analyzed time dependent global proteomic adaptations during heart failure (HF) progression in a mouse model, suffering from left ventricular pressure overload due to transverse aortic constriction (TAC), to gain deeper insights in the disease development and identify new biomarker candidates. The hearts from TAC and sham mice were examined by cardiac MRI on either day 4, 14, 21, 28, 42, and 56 after surgery (n=6 group/time point). At each time point, proteomes of the left (LV) and right ventricles (RV) of TAC and sham mice were analyzed by mass spectrometry (MS).

2018-07-16 | PXD007171 | Pride

MHC-I peptidome analysis of human cancer cell lines

Project description:In this study, we sought to identify naturally presented MHC peptides in 8 human cancer cell lines: PANC.1, A.375, SW527, CaSki, PC.3, LNCaP_clone_FGC, MCF.7, and VMRC.LCD. Peptides identified were 8-15 amino acid long with the majority between 8 to 11 amino acids which match known properties of MHC-I presented peptides. Number of identifications differs between cell lines and ranges between 1834-5425 peptides.

2021-09-09 | PXD022020 | Pride

MHC-I peptidome analysis of human cancer cell lines

Project description:In this study, we sought to identify naturally presented MHC peptides in 3 human cancer cell lines: A431, Colo668, HuCCT1. Peptides identified were 8-15 amino acid long with the majority between 8 to 11 amino acids which match known properties of MHC-I presented peptides.

2022-05-09 | PXD033685 | Pride

Chronic iron limitation induces resistance to ROS

Project description:Diatoms are single celled photosynthetic bloom-forming algae that are responsible for at least 20% of global primary production. Nevertheless, more than 30% of the oceans are considered “ocean deserts” due to iron limitation. We used the diatom Phaeodactylum tricornutum as a model system to explore diatom’s response to iron limitation and its interplay with susceptibility to oxidative stress. By analyzing physiological parameters and proteome profiling, we defined two distinct phases: short-term (< 3 days, phase I) and chronic (> 5 days, phase II) iron limitation. While at phase I no changes in physiological parameters were observed, molecular markers for iron starvation, such as ISIP and flavodoxin, were highly upregulated. At phase II, down regulation of numerous iron-containing proteins was detected in parallel to reduction in growth rate, chlorophyll content, photosynthetic activity, respiration rate and antioxidant capacity. Intriguingly, while application of oxidative stress to phase I and II iron limited cells similarly oxidized the GSH pool, phase II iron limitation exhibited transient resistance to oxidative stress, despite the down regulation of many antioxidant proteins. By comparing proteomic profiles of P. tricornutum under iron limitation and metatranscriptomic data of an iron enrichment experiment conducted in the Pacific Ocean, we propose that iron limited cells in the natural environment resemble the phase II metabolic state. These results provide insights into the trade-off between maximal growth rate and susceptibility to oxidative stress as a possible key determinant in the response of diatoms to iron quota in the marine environment.

2017-01-16 | PXD004694 | Pride

Proteomic analysis of sea urchin egg provisioning and development

Project description:Here we present LC-MS/MS proteomic datasets of Heliocidaris erythrogramma, Heliocidaris tuberculata, and Lytechinus variegatus eggs and larvae. We find dramatic proteomic differences likely associated with life history evolution and between developmental stages. This study provides a complimentary dataset to previous transcriptomic analyses of the same three sea urchin species.

2019-03-04 | PXD007065 | Pride

Microarray analysis among non-alcoholic fatty liver, non-alcoholic steatohepatitis, and type 2 diabetes mellitus rats

Project description:Non-alcoholic fatty liver (NAFL) has the potential to progress to non-alcoholic steatohepatitis (NASH) or to promote type 2 diabetes mellitus (T2DM). However, NASH and T2DM do not always develop coordinately. We established rat models of NAFL, NASH, and NAFL + T2DM to recapitulate different phenotypes associated with NAFLD and its progression. Microarrays were used to identify hepatic gene expression changes in each of these models. The goal is to identify a predictor of different NAFLD progressions. Non-alcoholic fatty liver disease (NAFLD) is recognized as a low-grade systemic inflammatory state with both hepatic and extra-hepatic manifestations. We aimed to identify common key regulators and adaptive pathways in different NAFLD phenotypes. NAFL, NASH and NAFL+T2DM rat models were used to represent simple fatty liver, fatty liver with severe hepatic manifestations, and fatty liver with severe metabolic manifestations, respectively. We applied microarray analysis to characterize the key regulators and adaptive pathways in different NAFLD phenotypes. There are 12 samples in our study which belonged to 4 groups, and each group contains 3 different samples.

2015-01-23 | E-GEOD-65220 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data